Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596)
69.00
-1.00 (-1.43%)
Aug 27, 2026, 12:45 PM JST
TYO:4596 Revenue
Kubota Pharmaceutical Holdings had revenue of 2.31M JPY in the quarter ending June 30, 2026, a decrease of -51.50%. This brings the company's revenue in the last twelve months to 16.00M, down -46.67% year-over-year. In the year 2025, Kubota Pharmaceutical Holdings had annual revenue of 21.00M, down -22.22%.
Revenue (ttm)
16.00M
Revenue Growth
-46.67%
P/S Ratio
709.38
Revenue / Employee
n/a
Employees
8
Market Cap
11.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.00M | -6.00M | -22.22% |
| Dec 31, 2024 | 27.00M | -12.00M | -30.77% |
| Dec 31, 2023 | 39.00M | 31.00M | 387.50% |
| Dec 31, 2022 | 8.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.14B |
| StemCell Institute | 2.81B |
| ReproCELL | 2.30B |
| Immuno-Biological Laboratories | 1.08B |
| OncoTherapy Science | 777.00M |
| Carna Biosciences | 729.00M |
| SUSMED,Inc. | 497.00M |
| Stella Pharma | 323.00M |